Do growth hormone peptides build muscle?

No controlled trial has shown muscle gain in healthy adults from sermorelin, CJC-1295 or ipamorelin. They raise GH and IGF-1 levels; that laboratory change has not translated into a demonstrated body-composition outcome.

Is CJC-1295 FDA approved?

No. CJC-1295 is not FDA-approved and was removed from 503A Category 2 in April 2026 without being placed in Category 1, so compounding is not covered by the 503A exemption as of September 2026.

Which GH-axis peptide is approved in the US?

Sermorelin holds a historical approval for paediatric growth hormone deficiency and tesamorelin is approved for HIV-associated lipodystrophy. Neither is approved for body composition in healthy adults.

§ — Researched for · Muscle, body composition & growth hormone axis

Peptides researched for muscle, body composition & growth hormone axis

Growth-hormone-axis peptides — sermorelin, CJC-1295, ipamorelin, tesamorelin — reliably raise GH and IGF-1 in humans. What none of them has shown in controlled trials is the fat loss, muscle gain or 'anti-aging' outcome that marketing attaches to them, and only tesamorelin holds an FDA approval, for a narrow HIV-related indication.

Approved drug with randomized controlled trials for the approved indication

Human clinical data exists, but no approval for the researched use

Animal or in-vitro data only, no controlled human trials

No published clinical data; use rests on anecdote

Reviewed September 2026 · Sources: FDA, EMA

02 — What is being studied

The research field, in plain terms.

The field studies secretagogues: molecules that prompt the pituitary to release its own growth hormone rather than replacing it. The pharmacological endpoints — peak GH, 24-hour GH output, IGF-1 concentration — are well characterised in phase 1 and phase 2 work going back to the 1990s. On those measures the class does what it is described as doing.

The clinical endpoints are the open question. Lean mass measured by DEXA, visceral fat, strength, and any functional outcome in healthy adults have not been established in controlled trials for sermorelin, CJC-1295 or ipamorelin. Tesamorelin is the exception with trial-backed visceral fat reduction, and only in HIV-associated lipodystrophy. Raising a hormone is a laboratory result; changing body composition or function is a clinical result, and the second has not followed from the first in published data as of September 2026.

03 — The table

Every peptide in this group, with its status.

Peptide	Researched for	Evidence	Regulatory status	As of
Sermorelin	Growth hormone deficiency; GH axis stimulation in adults.	A	Previously FDA-approved as Geref for pediatric growth hormone deficiency and diagnostic use; the approved product was discontinued in 2008 for commercial reasons. Widely compounded; its 503A basis must be verified against the current bulks list before publication.	2026-09-06
Tesamorelin	Visceral fat reduction in HIV lipodystrophy; NAFLD; cognitive function in older adults.	A	FDA-approved (Egrifta) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Use for any other purpose is off-label.	2026-09-06
CJC-1295	Sustained growth hormone and IGF-1 elevation in adults; body composition.	B	Not FDA-approved. Removed from 503A Category 2 in April 2026 following nomination withdrawal; not placed in Category 1. Compounding not covered by the 503A exemption.	2026-09-06
Ipamorelin	Postoperative ileus (a completed phase 2 program); growth hormone release.	B	Not FDA-approved. Placed in 503A Category 2 in 2023. Its current category must be verified against the FDA bulks list before publication; it has not been listed in Category 1.	2026-09-06

04 — Per peptide

Status first, then research.

Sermorelin

Regulatory status · United States · as of September 2026

Previously FDA-approved as Geref for pediatric growth hormone deficiency and diagnostic use; the approved product was discontinued in 2008 for commercial reasons. Widely compounded; its 503A basis must be verified against the current bulks list before publication.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forGrowth hormone deficiency; GH axis stimulation in adults.

Full profile: Sermorelin →

Tesamorelin

Regulatory status · United States · as of September 2026

FDA-approved (Egrifta) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Use for any other purpose is off-label.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forVisceral fat reduction in HIV lipodystrophy; NAFLD; cognitive function in older adults.

Full profile: Tesamorelin →

CJC-1295

Regulatory status · United States · as of September 2026

Not FDA-approved. Removed from 503A Category 2 in April 2026 following nomination withdrawal; not placed in Category 1. Compounding not covered by the 503A exemption.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forSustained growth hormone and IGF-1 elevation in adults; body composition.

Full profile: CJC-1295 →

Ipamorelin

Regulatory status · United States · as of September 2026

Not FDA-approved. Placed in 503A Category 2 in 2023. Its current category must be verified against the FDA bulks list before publication; it has not been listed in Category 1.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forPostoperative ileus (a completed phase 2 program); growth hormone release.

Full profile: Ipamorelin →

05 — What the data does not show

The limits of this group.

Fat loss, lean mass gain and any anti-aging outcome in healthy adults have not been shown in controlled trials for any GH-axis peptide.

06 — Questions for your physician

Six questions worth printing.

01What is your primary board certification, and in what year did you obtain it?
02Is this peptide approved for what you are prescribing it for — and if not, what is the legal basis on which you are supplying it?
03Which human trials support this use, and what were their size and duration?
04Where does the product come from, and can you show me a certificate of analysis for this batch?
05What outcome will we measure, when, and what happens if it does not improve?
06What is the total cost for the first three months, in writing?

Providers in the registry offering peptide therapy

Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.

Longevity network

Longevity Centers of America (Netzwerk)

Hormone therapy (HRT / BHRT)
Peptide therapy

ListedView profile →

Age-management practice

Micah Olson, MD - Age Management Biltmore

Phoenix, AZ

VO2max testing
Hormone therapy (HRT / BHRT)
Peptide therapy
DEXA body composition

ListedView profile →

Reviewed September 2026 · Sources: FDA, EMA

This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.